DB04928InvestigationalSmall molecule
XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.
- Primary indication
- Investigated for use/treatment in menstrual disorders.Curator reviewed
- Code names
- XP12B
What you can answer from here — as of April 02, 2025
Which companies are running trials of XP12B, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account